Checkmate 816: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum doublet chemotherapy as neoadjuvant treatment for early-stage NSCLC Meeting Abstract
| Authors: | Forde, P. M.; Chaft, J. E.; Felip, E.; Broderick, S.; Girard, N.; Awad, M. M.; Kerr, K.; Blackwood-Chirchir, A.; Yang, R.; Geese, W. J.; Brahmer, J. R. |
| Abstract Title: | Checkmate 816: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum doublet chemotherapy as neoadjuvant treatment for early-stage NSCLC |
| Meeting Title: | 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 35 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2017 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2017-05-20 |
| Start Page: | 445s |
| Language: | English |
| ACCESSION: | WOS:000411932201154 |
| DOI: | 10.1200/JCO.2017.35.15_suppl.TPS8577 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS8577 -- Source: Wos |
